Raydiant Oximetry

Raydiant Oximetry is pioneering a technological transformation in intrapartum fetal monitoring to address the high rates of maternal and neonatal morbidity and the overuse of cesarean deliveries. Its lead product, Lumerah™, is a noninvasive fetal pulse oximeter that has received FDA Breakthrough Device designation and is progressing through clinical studies, including an IDE Pilot Study. The company is backed by venture capital, strategic grants, and a key partnership with GE HealthCare, positioning it to address a critical unmet need in the $5B+ global fetal monitoring market.

Proprietary biophotonics and machine learning platform for noninvasive fetal pulse oximetry, designed to isolate and measure fetal oxygen saturation (FSpO2) through maternal tissue.

Raydiant's direct competition includes other companies developing fetal pulse oximetry or alternative intrapartum monitoring technologies, though none currently have an FDA-cleared noninvasive device for continuous fetal SpO2 monitoring. The broader competitive landscape is dominated by established electronic fetal monitor manufacturers (e.g., GE HealthCare, Philips, Edan), whose systems Raydiant aims to augment rather than replace. Its Breakthrough status and GE partnership provide a distinct competitive advantage.